



**Ongoing Disclosure Notice**

**Disclosure of Directors and Senior Managers Relevant Interests**

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Fisher & Paykel Healthcare Corporation Limited
6 July 2020
25 September 2019

**Director or senior manager giving disclosure**

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

<b>Lewis George GRADON</b>
Fisher & Paykel Healthcare Corporation Limited
Chief Executive Officer

**Summary of acquisition or disposal of relevant interest (excluding specified derivatives)**

Class of affected quoted financial products:
Nature of the affected relevant interest(s):
<b>For that relevant interest:</b>
Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

(a) Options to acquire Ordinary Shares (b) Ordinary Shares Beneficial Interest
(a) 465,504 Options to acquire Ordinary Shares (b) 603,502 Ordinary Shares
(a) 350,504 Options to acquire Ordinary Shares (b) 553,649 Ordinary Shares
Lewis George Gradon and Gradon Family Trust
Lewis George Gradon and Gradon Family Trust

**Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)**

Type of affected derivative:
Class of underlying financial products:
<b>Details of affected derivative:</b>
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
<i>For that derivative:</i>
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Not Applicable

**Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:
<b>Details of transactions requiring disclosure:</b>
Date of transaction:
Nature of transaction:
Name of any other party or parties to the transaction (if known):

Two
(a) 02 July 2020 (b) 02 July 2020
(a) Cancellation of 115,000 Options and issue of 86,147 Ordinary Shares (b) Sale of 136,000 Ordinary Shares

The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:

(a) \$3,039,293  
(b) \$4,665,765.60  
(a) 115,000 Options to acquire Ordinary Shares and 86,147 Ordinary Shares  
(b) 136,000 Ordinary Shares

Number of financial products to which the transaction related:  
*If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details:*

Whether relevant interests were acquired or disposed of during a closed period:  
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:  
Date of the prior written clearance (if any):

**Summary of other relevant interests after acquisition or disposal**

Class of quoted financial products:  
Nature of relevant interest:

*For that relevant interest:*  
Number held in class:  
Current registered holder(s):

*For a derivative relevant interest:*  
Type of derivative:


Not Applicable

**Details of derivative:**  
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):  
A statement as to whether the derivative is cash settled or physically settled:  
Maturity date of the derivative (if any):  
Expiry date of the derivative (if any):  
The price's specified terms (if any):  
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:  
*For that derivative relevant interest:*  
Parties to the derivative:  
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

**Certification**

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:  
Date of signature:

  
6 July 2020

or  
Signature of person authorised to sign on behalf of director or officer:  
Date of signature:  
Name and title of authorised person:



## Ongoing Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Fisher & Paykel Healthcare Corporation Limited
6 July 2020
6 December 2019

#### Director or senior manager giving disclosure

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Michael Grenfell Daniell
Fisher & Paykel Healthcare Corporation Limited
Not Applicable
Director

#### Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:
Nature of the affected relevant interest(s):

a) Ordinary Shares
b) Options to Acquire Ordinary Shares
Beneficial Interest

#### For that relevant interest:

Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

a) 974,267
b) 20,000
a) 900,168
b) 0
Michael Grenfell Daniell and Daniell Family Trust
Michael Grenfell Daniell and Daniell Family Trust

#### Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:
Class of underlying financial products:

#### Details of affected derivative:

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

#### For that derivative:

Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

#### Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:
---

Two
-----

#### Details of transactions requiring disclosure:

Date of transaction:
Nature of transaction:
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:
Number of financial products to which the transaction related:

a) 1/07/2020
b) 2/07/2020
a) Sale of 90,000 Ordinary Shares
b) Cancellation of 20,000 Options and issue of 15,901 Ordinary Shares
a) \$3,084,209.41
b) \$561,004.00
a) 90,000 Ordinary Shares
b) 20,000 Options to acquire Ordinary Shares and 15,901 Ordinary Shares

If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details:

Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:
Date of the prior written clearance (if any):


**Summary of other relevant interests after acquisition or disposal**

Class of quoted financial products:
Nature of relevant interest:


*For that relevant interest:*

Number held in class:
Current registered holder(s):


*For a derivative relevant interest:*

Type of derivative:
---------------------

--

**Details of derivative:**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
---

--

A statement as to whether the derivative is cash settled or physically settled:
---

--

Maturity date of the derivative (if any):
---

--

Expiry date of the derivative (if any):
---

--

The price's specified terms (if any):
---------------------------------------

--

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
---

--

*For that derivative relevant interest:*

Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:


**Certification**

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.
---

Signature of director or officer:
-----------------------------------


---

Date of signature:
--------------------

6 July 2020
-------------

or

Signature of person authorised to sign on behalf of director or officer:
--

--

Date of signature:
--------------------

--

Name and title of authorised person:
--------------------------------------

--



**Ongoing Disclosure Notice**

**Disclosure of Directors and Senior Managers Relevant Interests**

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Fisher & Paykel Healthcare Corporation Limited
6 July 2020
25 September 2019

**Director or senior manager giving disclosure**

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Paul Nigel Shearer
Fisher & Paykel Healthcare Corporation Limited
Senior Vice President - Sales & Marketing

**Summary of acquisition or disposal of relevant interest (excluding specified derivatives)**

Class of affected quoted financial products:
Nature of the affected relevant interest(s):
<b>For that relevant interest-</b>
Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

(a) Options to acquire Ordinary Shares (b) Ordinary Shares
Beneficial
(a) 238,031 (b) 405,398
(a) 180,853 (b) 404,661
Paul Nigel Shearer and Shearer Family Trust
Paul Nigel Shearer and Shearer Family Trust

**Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)**

Type of affected derivative:
Class of underlying financial products:
<b>Details of affected derivative-</b>
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative(if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
<i>For that derivative,-</i>
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

Not Applicable

**Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:
<b>Details of transactions requiring disclosure-</b>
Date of transaction:

Two
(a) 02 July 2020 (b) 01 and 02 July 2020

Nature of transaction:
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration:
Number of financial products to which the transaction related: <i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i>
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:
Date of the prior written clearance (if any):

(a) Cancellation of 57,178 Options and issue of 41,263 Ordinary Shares (b) Sale of 42,000 Ordinary Shares
(a) \$1,455,763.31 (b) \$1,289,181.51
(a) 57,178 Cancellation of Options and issue of 41,263 Ordinary Shares (b) 42,000 Ordinary Shares

**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:
Nature of relevant interest:
<i>For that relevant interest,-</i> Number held in class:
Current registered holder(s):
<i>For a derivative relevant interest,-</i> Type of derivative:


**Details of derivative,-**


The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
<i>For that derivative relevant interest,-</i> Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:


**Cerification**

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:
Date of signature:


or Signature of person authorised to sign on behalf of director or officer:
Date of signature:
Name and title of authorised person:


6/07/2020
Marcus Driller, Company Secretary



**Ongoing Disclosure Notice**

**Disclosure of Directors and Senior Managers Relevant Interests**

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and
Name of listed issuer:
Date this disclosure made:
Date of last disclosure:

Fisher & Paykel Healthcare Corporation Limited
6 July 2020
4 December 2019

**Director or senior manager giving disclosure**

Full name(s):
Name of listed issuer:
Name of related body corporate (if applicable):
Position held in listed issuer:

Scott Andrew St John
Fisher & Paykel Healthcare Corporation Limited
Director

**Summary of acquisition or disposal of relevant interest (excluding specified derivatives)**

Class of affected quoted financial products:
Nature of the affected relevant interest(s):
<b>For that relevant interest:</b>
Number held in class before acquisition or disposal:
Number held in class after acquisition or disposal:
Current registered holder(s):
Registered holder(s) once transfers are registered:

Ordinary Shares
Beneficial Interest
17,500
19,000
FNZ Custodians as Custodian for Scott Andrew St John
FNZ Custodians as Custodian for Scott Andrew St John

**Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)**

Type of affected derivative:
Class of underlying financial products:
<b>Details of affected derivative:</b>
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price specified in the terms of the derivative (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
<i>For that derivative:</i>
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:


**Details of transactions giving rise to acquisition or disposal**

Total number of transactions to which notice relates:
<b>Details of transactions requiring disclosure:</b>
Date of transaction:
Nature of transaction:
Name of any other party or parties to the transaction (if known):
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:
Number of financial products to which the transaction related:
<i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details:</i>
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:

Two
1 July 2020
Purchase of Ordinary Shares
\$52,330
1,500

Date of the prior written clearance (if any):

**Summary of other relevant interests after acquisition or disposal**

Class of quoted financial products:

Nature of relevant interest:

*For that relevant interest:*

Number held in class:

Current registered holder(s):

*For a derivative relevant interest:*

Type of derivative:

**Details of derivative:**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled:

Maturity date of the derivative (if any):

Expiry date of the derivative (if any):

The price's specified terms (if any):

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:

*For that derivative relevant interest:*

Parties to the derivative:

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

**Certification**

I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:

Date of signature:

or

Signature of person authorised to sign on behalf of director or officer:



Date of signature:

6 July 2020

Name and title of authorised person:

Marcus Driller, Company Secretary